SEC Form 4 · accession 0001104659-15-029245
T2 Biosystems, Inc. · TTOO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas J. Lowery
Officer — Chief Scientific Officer
Period of report
Apr 20, 2015
Accepted (ET)
Apr 22, 2015 · 11:14 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492674
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 20, 2015 | M | 1,000 | $1.16 | A | 6,882 | D | |
| Common StockF2 | Apr 20, 2015 | S | 1,000 | $18.426 | D | 5,882 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $1.16 | Apr 20, 2015 | M | 1,000 | A | Feb 27, 2013 | Feb 27, 2019 | Common Stock | 1,000 | 22,529 | D |
Explanation of responses
- F1The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2015.
- F2The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $18.20 to $18.81. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.